Table 5.
Pathway analysis of the predicted target genes of LINC00996
| Title | Count | P-value | Genes |
|---|---|---|---|
| Hematopoietic cell lineage | 7 | 5.10×10−6 | ITGA4 CD19 MS4A1 CD2 CD38 CD1C IL7R |
| Primary immunodeficiency | 5 | 2.22×10−5 | BTK CD19 CD79A IL7R PTPRC |
| Cytokine–cytokine receptor interaction | 8 | 2.05×10−4 | CCR7 IL2RB TNFRSF17 IL10RA CSF2RB IL7R IL18R1 CD27 |
| B cell receptor signaling pathway | 5 | 2.50×10−4 | BTK PRKCB CD19 CD79A PIK3CG |
| JAK-STAT signaling pathway | 6 | 5.93×10−4 | STAT4 IL2RB PIK3CG IL10RA CSF2RB IL7R |
| Leukocyte transendothelial migration | 5 | 1.52×10−3 | ITGA4 PRKCB PIK3CG CYBB RASSF5 |
| Cell adhesion molecules (CAMs) | 5 | 3.41×10−3 | SELL ITGA4 HLA-DOA CD2 PTPRC |
| NF-κB signaling pathway | 4 | 6.07×10−3 | BTK PRKCB ATM LY96 |
| Transcriptional misregulation in cancer | 5 | 6.78×10−3 | MEF2C CCR7 ATM IL2RB CCNT2 |
| Intestinal immune network for IgA production | 3 | 1.08×10−2 | ITGA4 HLA-DOA TNFRSF17 |
| Toxoplasmosis | 4 | 1.08×10−2 | HLA-DOA LY96 PIK3CG IL10RA |
| Non-small-cell lung cancer | 3 | 1.29×10−2 | PRKCB PIK3CG RASSF5 |
| Inflammatory bowel disease (IBD) | 3 | 1.88×10−2 | HLA-DOA STAT4 IL18R1 |
| Oxytocin signaling pathway | 4 | 2.23×10−2 | MEF2C PRKCB CD38 PIK3CG |
| Leishmaniasis | 3 | 2.23×10−2 | ITGA4 HLA-DOA PRKCB |
| Neuroactive ligand-receptor interaction | 5 | 2.51×10−2 | P2RY14 P2RY8 P2RY13 P2RY10 CYSLTR1 |
| Influenza A | 4 | 2.82×10−2 | HLA-DOA PRKCB TLR7 PIK3CG |
| Fc gamma R-mediated phagocytosis | 3 | 3.46×10−2 | PRKCB PIK3CG PTPRC |
| AGE-RAGE signaling pathway in diabetic complications | 3 | 3.91×10−2 | PRKCB PIK3CG CYBB |
| Epstein–Barr virus infection | 4 | 3.91×10−2 | CD19 CD38 PIK3CG IL10RA |
| HIF-1 signaling pathway | 3 | 3.91×10−2 | PRKCB PIK3CG CYBB |
| Toll-like receptor signaling pathway | 3 | 4.04×10−2 | LY96 TLR7 PIK3CG |
| PI3K-AKT signaling pathway | 5 | 4.12×10−2 | ITGA4 CD19 IL2RB PIK3CG IL7R |
Note: The pathway analysis was performed in Kyoto Encyclopedia of Genes and Genomes database, and there were 23 available pathways that were significant (P<0.05).